Enara Bio

We are looking forward to the Dark Genome Symposium next week! Jo Senra, our Director of Preclinical Validation, will be presenting a poster on our exciting work to discover novel cancer-specific #DarkAntigens in gastrointestinal tumors.   There is still time to register to participate virtually here: https://lnkd.in/ed5TrCgw   #DarkGenome #DGS2024 #EnaraBio

We are delighted to be co-hosting the Dark Genome Symposium again this year with NYU Langone Health, ROME Therapeutics and Nucleome Therapeutics. Our CSO, Joe Dukes, is participating in an exciting panel discussion on the promise of Dark Antigens. See his thoughts on the field here: #DarkAntigens #DarkGenome #DGS2024 #Immunotherapy #EnaraBio #Biotech

Join us together with co-hosts ROME Therapeutics, Nucleome Therapeutics, and NYU Langone Health at the Dark Genome Symposium next month. The agenda covers a broad range of dark genome science with a world-class lineup of speakers and panelists. Learn how to participate below 👇: #DGS2024 #DarkGenome #DarkAntigens

We are thrilled to announce the closing of our $32.5 million Series B financing! The financing was co-led by two new strategic investors, Pfizer Ventures and M Ventures . All existing investors also joined the round – RA Capital Management, Samsara BioCapital and SV Health Investors – along with participation from the The Francis Crick Institute. The funding allows us to continue our pioneering research on Dark Antigens – a novel class of shared cancer antigens – and rapidly advance our pipeline of TCR-based immunotherapies against these exciting new targets. Follow the link for our full press release and to learn more about Dark Antigens: https://lnkd.in/ejVHURzk #DarkAntigens #DarkGenome #Immunotherapy #EnaraBio #Biotech

We are excited by the superb lineup of speakers and panelists again this year at the #DarkGenomeSymposium!! #DGS2024 #DarkGenome #DarkAntigens

Last week, it was a great pleasure to host a work placement experience and welcome several students from the In2STEM summer programme for a second year. At Enara Bio, we are deeply committed to diversity and social mobility and were delighted to share our insights and experiences on the wide range of STEM career paths that are available to all students regardless of their backgrounds. The students had the opportunity to observe the groundbreaking research in our labs and enjoyed several workshops with colleagues from different roles across our organisation. It was inspiring to hear about their future aspirations in STEM! #enarabio #In2STEM #In2scienceUK In2scienceUK

The countdown has started to the 3rd Annual Dark Genome Symposium in New York. See below for details of how to submit abstracts on your research! #DarkAntigens #DarkGenome #DarkGenomeSymposium #DGS2024

After tremendous success the last two years, we are delighted to be co-hosting the 3rd Annual Dark Genome Symposium in New York on 20-21 November 2024. The event brings together leaders from academia, industry, and the investment community to discuss future directions in dark genome research and the development of novel therapeutics. See below for details on how to register for the symposium or submit abstracts on your research. We look forward to seeing you there! #DarkAntigens #DarkGenome #DarkGenomeSymposium #DGS2024 

Sunday is World Cancer Day. At Enara Bio, we are proud to be at the cutting edge of the global effort to prevent, treat, and cure cancer. We are committed to our goal of finding novel immunotherapy targets from the Dark Genome and developing innovative treatments that will improve survival outcomes for cancer patients.     To mark World Cancer Day, this week our Sports and Social Team arranged our first charity morning of the year. It was great to take time to raise money for charities that provide tireless support for cancer patients. A great cause that links so closely with the work we do at Enara.  #worldcancerday  #closethecaregap #DarkAntigens #DarkGenome #EnaraBio #Biotech 

At Enara Bio, we are firm believers that collaboration is an essential part of advancing science and developing new treatments for patients. Our partnership with Boehringer Ingelheim has been a key part of our mission to shine a light on the dark genome to discover novel insights into cancer. We are delighted that by licensing multiple Dark Antigens discovered via our EDAPT platform, Boehringer Ingelheim can advance the next generation of cancer vaccines for the treatment of lung cancer. #DarkAntigens #DarkGenome #Collaboration #EnaraBio #Biotech